Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
24.99
+1.19 (5.00%)
At close: Aug 13, 2025, 4:00 PM
24.06
-0.93 (-3.72%)
Pre-market: Aug 14, 2025, 8:48 AM EDT
Celldex Therapeutics Employees
Celldex Therapeutics had 186 employees as of December 31, 2024. The number of employees increased by 26 or 16.25% compared to the previous year.
Employees
186
Change (1Y)
26
Growth (1Y)
16.25%
Revenue / Employee
$31,129
Profits / Employee
-$1,073,167
Market Cap
1.66B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CLDX News
- 6 days ago - Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewsWire
- 2 months ago - Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 - GlobeNewsWire
- 2 months ago - Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress - GlobeNewsWire
- 2 months ago - Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors - GlobeNewsWire
- 3 months ago - Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease - GlobeNewsWire
- 5 months ago - Celldex Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire